Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?-Reference-Cited by-同舟云学术

Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?

Published:2022-06-21 Issue:5 Volume:40 Page:835-842
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

D’Arena Giovanni¹^ORCID,Sgambato Alessandro²,Volpe Silvestro³,Coppola Giuseppe⁴,Amodeo Rachele⁵,Tirino Virginia⁶,D’Auria Fiorella⁷,Statuto Teodora⁷,Valvano Luciana⁷,Pietrantuono Giuseppe¹,Deaglio Silvia⁸,Efremov Dimitar⁹,Laurenti Luca¹⁰^ORCID,Aiello Antonella¹¹

Affiliation:

1. Hematology and Stem Cell Transplantation Unit IRCCS Centro di Riferimento Oncologico della Basilicata Rionero in Vulture Italy

2. Scientific Direction IRCCS Centro di Riferimento Oncologico della Basilicata Rionero in Vulture Italy

3. Immunohematology Unit AORN Giuseppe Moscati Avellino Italy

4. Immunohematology Unit AOU San Giovanni di Dio e Ruggi d’Aragona Salerno Italy

5. Flow Cytometry Unit Clinical Laboratory Sant’Andrea Hospital Roma Italy

6. Department of Experimental Medicine University of Campania “Luigi Vanvitelli” Napoli Italy

7. Laboratory of Clinical and Advanced Diagnostics IRCCS Centro di Riferimento Oncologico della Basilicata Rionero in Vulture Italy

8. Department of Medical Sciences University of Torino Torino Italy

9. Molecular Hematology International Center for Genetic Engineering and Biotechnology Trieste Italy

10. Hematology Unit IRCCS Fondazione Policlinico Gemelli Catholic University of “Sacred Heart” Roma Italy

11. Department of Pathology and Laboratory Medicine Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3037

Reference42 articles.

1. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival

3. Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

4. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable residual disease in chronic lymphocytic leukemia;Frontiers in Oncology;2023-02-14